S-1/A: Arch Therapeutics Eyes Cboe Listing with Unit Offering, Aims to Bolster Commercialization Efforts

Arch Therapeutics is undertaking a unit offering to support its Cboe listing application and fuel the commercial rollout of its AC5 Advanced Wound System.

Summary

• Arch Therapeutics is seeking to list its Common Stock on the Cboe BZX Exchange and is offering units, each consisting of one share of Common Stock and one Investor Warrant, as well as pre-funded units.
• The company intends to use the net proceeds from this offering for product marketing and general working capital.
• The offering is contingent upon Cboe or an Alternate Exchange approving the listing of Arch's Common Stock by June 30, 2024.
• In connection with the offering, Arch intends to effect a 1-for-8 reverse stock split.
• The company has also entered into a Securities Purchase Agreement with certain investors for the issuance and sale of Secured Promissory Notes convertible into shares of Common Stock.
• The company has an aggregate of $6,898,221 in principal outstanding as of June 19, 2024 under the 2022 Notes and an aggregate of $2,400,000 in principal outstanding as of June 19, 2024 under the 2024 Notes.
• The company is obligated to complete an Uplist Transaction by June 30, 2024 to Cboe or an Alternate Exchange.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential for Cboe listing and commercialization efforts, the company's financial situation and dependence on future funding raise concerns.

Positives

• The company has a dedicated HCPCS Level II reimbursement code (A2020) for AC5 Advanced Wound System, which may enhance its ability to work with payors.
• AC5 Advanced Wound System has been added to major government contracting vehicles, enabling purchase by federal government agencies.
• Published case studies highlight the efficacy and safety of AC5 in treating challenging wounds, including limb salvage.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern.
• The company has incurred significant losses since inception and expects to continue incurring losses.
• The company will need substantial additional funding and may be unable to raise capital when needed.
• The company's obligations under the First Notes and 2024 Notes are secured by security interests in substantially all of its assets.
• The terms of the Bridge Offering, Uplist PIPE and 2022 Notes Financing could impose additional challenges on our ability to raise funding in the future.

Risks

• The company's commercial success depends on market acceptance of AC5 Advanced Wound System.
• The company faces competition from companies with greater resources.
• The company may be subject to costly and time-consuming litigation if others claim infringement on their intellectual property rights.
• There is not now, and there may not ever be, an active market for our Common Stock, which trades in the over-the-counter market in low volumes and at volatile prices.
• The company may not satisfy the listing requirements and thereby consummate an Uplist Transaction, including the requirement to have sufficient capital to satisfy our working capital requirements for at least one year, and the minimum bid price requirement to list on Cboe.

Future Outlook

The company expects the commercialization ramp to be gradual through 2024 and into 2025, while encouraging product use among key opinion leaders and early adopters in developing market channels, and then moderately accelerate.

Industry Context

The medical device, pharmaceutical and biotechnology industries are highly competitive, with rapid technological change and new product introductions. Arch Therapeutics faces competition from companies with greater resources and experience.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional shares.
• The company's ability to continue operations and develop its products depends on securing additional funding, which could impact employees and other stakeholders.

Next Steps

• Further develop product clinical profile.
• Enhance product packaging features.
• Identify and address opportunities for supply chain efficiencies.
• Assess technology platform to select product candidates for advancement.
• Seek additional funding to support operations.
• Continue to expand and enhance financial and operational reporting and controls.
• Pursue commercial partnerships.
• Expand and enhance intellectual property portfolio.

Key Dates

Keywords

Arch Therapeutics, AC5 Advanced Wound System, Cboe listing, unit offering, reverse stock split, biotechnology, wound care, securities, warrants, convertible notes